C4 Therapeutics and Betta Pharmaceuticals Ink $392M Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC
Portfolio Pulse from Benzinga Newsdesk
C4 Therapeutics (CCCC) and Betta Pharmaceuticals have signed a $392M licensing agreement for the development and commercialization of CFT8919, a BiDAC degrader for non-small cell lung cancer, in Greater China. C4T will receive $35M, including $10M upfront cash and a $25M equity investment, and is eligible for up to $357M in milestones and royalties.
May 30, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
C4 Therapeutics (CCCC) enters a $392M licensing agreement with Betta Pharmaceuticals for CFT8919 development in Greater China, receiving $35M upfront and being eligible for up to $357M in milestones and royalties.
The licensing agreement with Betta Pharmaceuticals will provide C4 Therapeutics with an upfront cash payment and a one-time equity investment, totaling $35M. Additionally, C4T is eligible for up to $357M in potential milestones and royalties, which could significantly boost its revenues. This deal is expected to have a positive short-term impact on CCCC's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100